Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

di Corbin, Amie S., Agarwal, Anupriya, Loriaux, Marc, Cortes, Jorge, Deininger, Michael W., Druker, Brian J.
Pubblicazione 2010

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

di Corbin, Amie S., Agarwal, Anupriya, Loriaux, Marc, Cortes, Jorge, Deininger, Michael W., Druker, Brian J.
Pubblicazione 2011

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

di Glover, Jason M, Loriaux, Marc, Tyner, Jeffrey W, Druker, Brian J, Chang, Bill H
Pubblicazione 2012

A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice

di Johnson, Kara J., Griswold, Ian J., O'Hare, Thomas, Corbin, Amie S., Loriaux, Marc, Deininger, Michael W., Druker, Brian J.
Pubblicazione 2009

Crosstalk between ROR1 and the pre-B-Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

di Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Pubblicazione 2012

HitWalker: variant prioritization for personalized functional cancer genomics

di Bottomly, Daniel, Wilmot, Beth, Tyner, Jeffrey W., Eide, Christopher A., Loriaux, Marc M., Druker, Brian J., McWeeney, Shannon K.
Pubblicazione 2013

Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance

di Viola, Shelton, Traer, Elie, Huan, Jianya, Hornick, Noah I., Tyner, Jeffrey W., Agarwal, Anupriya, Loriaux, Marc, Johnstone, Brian, Kurre, Peter
Pubblicato in Br J Haematol (2015)

Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth

di Dickerson, Erin B, Marley, Kevin, Edris, Wade, Tyner, Jeffrey W, Schalk, Vidya, MacDonald, Valerie, Loriaux, Marc, Druker, Brian J, Helfand, Stuart C
Pubblicazione 2013

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine

di Bottomly, Daniel, Ryabinin, Peter A, Tyner, Jeffrey W, Chang, Bill H, Loriaux, Marc M, Druker, Brian J, McWeeney, Shannon K, Wilmot, Beth
Pubblicazione 2013

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML

di Agarwal, Anupriya, Fleischman, Angela G., Petersen, Curtis L., MacKenzie, Ryan, Luty, Samuel, Loriaux, Marc, Druker, Brian J., Woltjer, Randall L., Deininger, Michael W.
Pubblicazione 2012

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

di Siegel, Matthew B., Liu, Selina Qiuying, Davare, Monika A., Spurgeon, Stephen E., Loriaux, Marc M., Druker, Brian J., Scott, Emma C., Tyner, Jeffrey W.
Pubblicato in Oncotarget (2015)

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

di Tyner, Jeffrey W., Bumm, Thomas G., Deininger, Jutta, Wood, Lisa, Aichberger, Karl J., Loriaux, Marc M., Druker, Brian J., Burns, Christopher J., Fantino, Emmanuelle, Deininger, Michael W.
Pubblicazione 2010

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia

di Paiva, Cody, Rowland, Taylor A., Sreekantham, Bhargava, Godbersen, Claire, Best, Scott R., Kaur, Prabhjot, Loriaux, Marc M., Spurgeon, Stephen E.F., Danilova, Olga V., Danilov, Alexey V.
Pubblicato in Haematologica (2017)

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

di Burke, Russell T, Meadows, Sarah, Loriaux, Marc M, Currie, Kevin S., Mitchell, Scott A., Maciejewski, Patricia, Clarke, Astrid S., Dipaolo, Julie A., Druker, Brian J., Lannutti, Brian J., Spurgeon, Stephen E.
Pubblicazione 2014

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

di Agarwal, Anupriya, Bumm, Thomas G. P., Corbin, Amie S., O'Hare, Thomas, Loriaux, Marc, VanDyke, Jonathan, Willis, Stephanie G., Deininger, Jutta, Nakayama, Keiichi I., Druker, Brian J., Deininger, Michael W.
Pubblicazione 2008

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition

di Fleischman, Angela G., Maxson, Julia E., Luty, Samuel B., Agarwal, Anupriya, Royer, Lacey R., Abel, Melissa L., MacManiman, Jason D., Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.
Pubblicazione 2013

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway

di Chang, Bill H, Johnson, Kara, LaTocha, Dorian, Rowley, Joelle S J, Bryant, Jade, Burke, Russell, Smith, Rebecca L, Loriaux, Marc, Müschen, Markus, Mullighan, Charles, Druker, Brian J, Tyner, Jeffrey W
Pubblicato in J Hematol Oncol (2015)

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

di Tyner, Jeffrey W., Walters, Denise K., Willis, Stephanie G., Luttropp, Mary, Oost, Jason, Loriaux, Marc, Erickson, Heidi, Corbin, Amie S., O'Hare, Thomas, Heinrich, Michael C., Deininger, Michael W., Druker, Brian J.
Pubblicazione 2008

RNAi screen for rapid therapeutic target identification in leukemia patients

di Tyner, Jeffrey W., Deininger, Michael W., Loriaux, Marc M., Chang, Bill H., Gotlib, Jason R., Willis, Stephanie G., Erickson, Heidi, Kovacsovics, Tibor, O'Hare, Thomas, Heinrich, Michael C., Druker, Brian J.
Pubblicazione 2009

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

di Tyner, Jeffrey W., Erickson, Heidi, Deininger, Michael W. N., Willis, Stephanie G., Eide, Christopher A., Levine, Ross L., Heinrich, Michael C., Gattermann, Norbert, Gilliland, D. Gary, Druker, Brian J., Loriaux, Marc M.
Pubblicazione 2009